Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 11/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | TMPRSS2 | O15393 | 4/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282219 | 0.81 | ALDH1A1 (0.43) | — | |
| SCHEMBL16303966 | 0.73 | ACE (0.50) | F11 | |
| SCHEMBL14861291 | 0.72 | F11 (0.59) | F11TRPM8KLKB1 | |
| SCHEMBL14874042 | 0.72 | F11 (0.59) | F11TRPM8KLKB1 | |
| SCHEMBL3281411 | 0.71 | PARP1 (0.43) | TRPM8 | |
| 4-Guanidino-Benzoic Acid SCHEMBL211005 | 0.70 | F2 (0.57) | — | |
| 4-Guanidino-Benzoic Acid SCHEMBL11123754 | 0.69 | F2 (0.55) | — | |
| 4-Guanidino-Benzoic Acid SCHEMBL22127093 | 0.69 | F2 (0.55) | — | |
| 4-Guanidino-Benzoic Acid SCHEMBL273175 | 0.69 | F2 (0.55) | — | |
| 4-Guanidino-Benzoic Acid SCHEMBL10674543 | 0.69 | F2 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705017-B2 | Compounds for treatment of neurodegenerative diseases | EN VIVO PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | claimed |
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | ENVIVO PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | claimed |
| WO-2005108367-A1 | COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | ENVIVO PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | WO | claimed |
| US-7705017-B2 | Compounds for treatment of neurodegenerative diseases | EN VIVO PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | ENVIVO PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| WO-2005108367-A1 | COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | ENVIVO PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | HDAC5, HDAC6, HDAC3 | F11 3930/4885TRPM8 3151/4885TMPRSS2 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.